問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林毅志

Recruiting

List

21Cases

2025-02-03 - 2029-12-23

Not yet recruiting
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of TPST-1120 in Combination With Atezolizumab Plus Bevacizumab Compared With Placebo Plus Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma (HCC) Not Previously Treated With Systemic Therapy

  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2025-09-26 - 2029-12-03

Others

Active
A Single-Arm, Phase IIIb Global, Multi-center Study of Durvalumab in Combination with Tremelimumab and Lenvatinib Given Concurrently with Locoregional Therapy in Participants with Locoregional Hepatocellular Carcinoma (EMERALD-CURE)

  • Condition/Disease

    Hepatocellular carcinoma

  • Test Drug

    Injection solution Injection solution Capsule solution

Participate Sites
2Sites

Recruiting2Sites

2025-12-15 - 2028-06-29

Phase I/II

Not yet recruiting
ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC)

  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    Infusion fluid

Participate Sites
4Sites

Recruiting4Sites

2023-09-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-03-01 - 2024-03-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2023-10-01 - 2030-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2025-04-01 - 2030-06-18

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2023-09-01 - 2027-04-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting3Sites

Recruiting5Sites

2023-08-01 - 2028-06-30

Others

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-01-01 - 2029-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB